Present and future of target therapies and theranostics: refining traditions and exploring new frontiers—highlights from annals of Nuclear Medicine 2021.

Present and future of target therapies and theranostics: refining traditions and exploring new frontiers - highlights from annals of Nuclear Medicine 2021 Conclusions This editorial spotlighted the central role of radionuclide therapy in the field of nuclear medicine showing the booming preclinical and clinical research on targeted therapy and theranostics, from the well-established treatment with iodine-131, to theranostics of neuroendocrine tumours and metastatic castration-resistant prostate cancer, to the field of new drug development. Iodine-131 is the standard of care treatment not only in hyperthyroidism, but also in well-differentiated thyroid cancer, for thyroid remnant ablation, adjuvant purposes and persistent/recurrent disease treatment [[23]]. Springer; 2021;35:529-39. 17 Huang K, Schatka I, Rogasch JMM, Lindquist RL, De Santis M, Erber B. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen. [Extracted from the article]